Earnings History Data for Biogen Inc. (BIIB) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Biogen Inc.

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia, and a deep clinical pipeline ranging from Alzheimer's disease, lupus nephritis to neuropathic pain.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
30-10-2024	PM		BIIB	Biogen Inc.	26,950	4.08	3.77	4.36	Biogen Non-GAAP EPS of $4.08 beats by $0.29, revenue of $2.46B beats by $30M [10/30/2024 6:55 AM]	181.21	-2.26 (-1.23%)	185.50	2.03 (1.11%)	177.93 - 268.30	1,333,694	1,170,000	20,545
Biogen, Neomorph to collaborate on clinical candidates for Alzheimer's [10/29/2024 7:05 PM] Biogen Q3 2024 Earnings Preview [10/29/2024 11:49 AM] Biogen names former Bristol-Myers executive as medical chief [10/29/2024 8:33 AM] Biogen Non-GAAP EPS of $4.08 beats by $0.29, revenue of $2.46B beats by $30M [10/30/2024 6:55 AM] Biogen raises 2024 EPS guidance with strong Q3 results [10/30/2024 12:06 PM] Biogen Sinks. Why A Surprise Boost From Its Alzheimer's Drug Wasn't Enough. [2024-10-30 10:14AM] Biogen (BIIB) Reports Q3 Earnings: What Key Metrics Have to Say [2024-10-30 09:30AM] Biogen Inc. (BIIB) Q3 Earnings and Revenues Surpass Estimates [2024-10-30 08:05AM] Biogen, Sage admit a defeat in major depression [2024-10-30 07:38AM] Biogen Earnings Top Views; Alzheimer's Drug Leqembi Gaining Momentum [2024-10-30 07:28AM] Eli Lilly stock sinks after Q3 earnings miss Wall Street expectations [2024-10-30 07:18AM] Biogen raises annual earnings guidance, tops Q3 estimates; shares up [2024-10-30 07:07AM] Biogen Raises Forecast as Alzheimers Drug Leqembi Shows Signs of Growth [2024-10-30 07:02AM] Biogen raises annual profit forecast as new treatments boost earnings [2024-10-30 06:54AM] Biogen optimistic as new products gain traction [2024-10-30 06:15AM] Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer's, Rare, and Immunological Diseases [Oct-29-24 06:00PM] Eli Lilly Q3 earnings misses Wall Street expectations, stock slips 10% in pre-market [Oct-29-24 05:03PM] Eli Lilly Q3 earnings expected to beat Wall Street expectations [Oct-29-24 05:03PM] Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer [Oct-29-24 08:00AM] Biogen refreshes its C-suite; Novartis writes down MorphoSys assets [Oct-29-24 05:54AM]
01-08-2024	PM		BIIB	Biogen Inc.	30,850	5.28	4.00	4.02	Biogen Non-GAAP EPS of $4.02 misses by $0.01, revenue of $2.46B beats by $70M [8/1/2024 7:08 AM]	210.66	-2.54 (-1.19%)	215.00	1.80 (0.84%)	189.44 - 278.95	1,514,898	1,220,000	25,344
Biogen Q2 2024 Earnings Preview [7/31/2024 12:02 PM] Biogen Non-GAAP EPS of $4.02 misses by $0.01, revenue of $2.46B beats by $70M [8/1/2024 7:08 AM] Biogen posts Q2 beat as sales from Alzheimer’s drug pick up [8/1/2024 8:50 AM]
24-04-2024	PM		BIIB	Biogen Inc.	28,220	3.67	3.44	3.40	Biogen Non-GAAP EPS of $3.67 beats by $0.21, revenue of $2.29B misses by $30M [4/24/2024 6:51 AM]	202.28	9.10 (4.71%)	200.67	7.49 (3.88%)	189.44 - 319.76	2,511,468	1,220,000	106,523
Biogen says uptake for Alzheimer’s therapy is improving [4/24/2024 8:03 AM] Biogen Non-GAAP EPS of $3.67 beats by $0.21, revenue of $2.29B misses by $30M [4/24/2024 6:51 AM] Biogen Q1 2024 Earnings Preview [4/23/2024 11:01 AM]
13-02-2024	PM		BIIB	Biogen Inc.	34,920	2.95	3.16	4.05	Biogen misses top-line and bottom-line estimates; initiates FY24 outlook [2/13/2024 7:18 AM]	226.73	-18.01 (-7.36%)	236.00	-8.74 (-3.57%)	220.86 - 319.76	2,958,381	910,000	19,523
Biogen gets EU approval for Friedrich's ataxia drug [2/12/2024 4:46 PM] Biogen Q4 2023 Earnings Preview [2/12/2024 11:21 AM] Biogen misses top-line and bottom-line estimates; initiates FY24 outlook [2/13/2024 7:18 AM] Biogen slips as outlook disappoints amid flat Leqembi sales [2/13/2024 7:59 AM]
08-11-2023	PM		BIIB	Biogen Inc.	36,010	4.36	3.97	4.77	Biogen Non-GAAP EPS of $4.36 beats by $0.37, revenue of $2.53B beats by $130M [11/8/2023 7:03 AM]	231.68	-13.93 (-5.67%)	246.20	0.59 (0.24%)	229.10 - 319.76	2,474,536	1,040,000	69,084
Biogen Q3 2023 Earnings Preview [11/7/2023 11:43 AM] Eisai sees a sharp rise in patients on Biogen-partnered Alzheimer’s drug [11/7/2023 6:59 AM] Biogen Non-GAAP EPS of $4.36 beats by $0.37, revenue of $2.53B beats by $130M [11/8/2023 7:03 AM] Biogen swings to Q3 growth after Reata acquisition (update) [11/8/2023 1:06 PM]
25-07-2023	PM		BIIB	Biogen Inc.	40,060	4.02	3.77	5.25	Biogen Non-GAAP EPS of $4.02 beats by $0.26, revenue of $2.46B beats by $100M [7/25/2023 7:14 AM]	270.11	-6.89 (-2.49%)	279.31	2.31 (0.83%)	193.65 - 319.76	2,104,423	1,260,000	20,390
Biogen Q2 2023 Earnings Preview [7/24/2023 12:15 PM] Biogen Non-GAAP EPS of $4.02 beats by $0.26, revenue of $2.46B beats by $100M [7/25/2023 7:14 AM] Biogen announces layoffs as focus turns to new products [7/25/2023 8:26 AM]
25-04-2023	PM	7:15 AM ET (Apr 25)	BIIB	Biogen Inc.	41,940	3.40	3.30	3.62	Biogen Non-GAAP EPS of $3.40 beats by $0.12, revenue of $2.46B beats by $120M [4/25/2023 7:03 AM]	282.40	-10.63 (-3.63%)	290.00	-3.03 (-1.03%)	187.16 - 311.88	1,263,862	700,000	3,513
Biogen Q1 results in focus amid Leqembi conundrum, ALS drug future [4/24/2023 11:52 AM] Biogen Non-GAAP EPS of $3.40 beats by $0.12, revenue of $2.46B beats by $120M [4/25/2023 7:03 AM] Biogen trims down R&D programs, Q1 revenue dips but reaffirms FY23 outlook [4/25/2023 8:01 AM] Hot Stocks: Earnings sparked movement in PEP, JBLU, NVS, MCD, BIIB and HAL [4/25/2023 1:10 PM] Biogen, Ionis win FDA nod for ALS therapy Qalsody [4/25/2023 3:11 PM]
15-02-2023	PM	7:15 AM ET (Feb 15)	BIIB	Biogen Inc.	41,230	4.05	3.51	3.39	Biogen beats Q4 top and bottom line estimates; initiates FY23 outlook [2/15/2023 7:15 AM]	278.64	-10.44 (-3.61%)	290.22	1.14 (0.39%)	187.16 - 311.88	1,386,834	820,000	8,063
Biogen's Alzheimer's therapy Aduhelm gets updated warning on brain hemorrhage risk [2/14/2023 11:51 AM] All eyes on Biogen Q4 results with focus on future of Alzheimer's drug Leqembi [2/14/2023 11:39 AM] Biogen beats Q4 top and bottom line estimates; initiates FY23 outlook [2/15/2023 7:15 AM] Biogen expects new Alzheimer’s drug to weigh on 2023 outlook [2/15/2023 11:15 AM]
25-10-2022	PM	7:00 AM ET (Oct 25)	BIIB	Biogen Inc.	38,830	4.77	4.13	4.77	Biogen Non-GAAP EPS of $4.77 beats by $0.66, revenue of $2.51B beats by $40M, raises FY22 outlook [10/25/2022 7:06 AM]	273.54	-1.08 (-0.39%)	277.00	2.38 (0.87%)	187.16 - 284.59	2,188,169	1,620,000	9,016
Biogen Q3 2022 Earnings Preview [10/24/2022 1:20 PM] Biogen Non-GAAP EPS of $4.77 beats by $0.66, revenue of $2.51B beats by $40M, raises FY22 outlook [10/25/2022 7:06 AM] Biogen raises guidance as topline outperforms amid ongoing cost management [10/25/2022 7:46 AM] US Earnings to Watch This Week: Apple, Microsoft, Boeing, Exxon, Biogen [Oct-24-22 08:23AM] With 86% ownership of the shares, Biogen Inc. (NASDAQ:BIIB) is heavily dominated by institutional owners [Oct-24-22 07:59AM] Three things investors will be looking for in Biogen's Q3 earnings [Oct-24-22 05:45AM]
20-07-2022	PM	7:20 AM ET (Jul 20)	BIIB	Biogen	31,782	5.25	4.10	0.00	Biogen Non-GAAP EPS of $5.25 beats by $1.16, revenue of $2.59B beats by $110M, raises FY22 guidance [7/20/2022 7:01 AM]	207.34	-12.92 (-5.87%)	217.39	-2.87 (-1.30%)	187.16 - 351.86	1,595,455	850,000	29,463
Biogen set to report Q2 result amid declining multiple sclerosis drug sales [7/19/2022 1:04 PM] Biogen Non-GAAP EPS of $5.25 beats by $1.16, revenue of $2.59B beats by $110M, raises FY22 guidance [7/20/2022 7:01 AM] Biogen raises guidance citing stronger than expected revenue and cost savings [7/20/2022 7:27 AM] Biogen agrees to pay $900M to settle whistleblower lawsuit [7/20/2022 1:15 PM] Ahead of Biogen Earnings, Here's What the Charts Say [Jul-19-22 08:59AM] Stock market news live updates: Stock futures struggle to build on Tuesday's rally [Jul-20-22 06:39AM] What Corporate America is really saying about the U.S. economy: Morning Brief [Jul-20-22 06:00AM] U.S. stocks extend rally as investors await Tesla earnings [Jul-20-22 11:02AM] Biogen beats Q2 earnings expectations, stock dips [Jul-20-22 10:06AM] Biogen's Quarterly Report Was 'Fine' Here's Why Shares Toppled [Jul-20-22 09:48AM] Stock market news live updates: Stocks struggle to build on Tuesday's rally at opening bell [Jul-20-22 09:33AM] Biogen (BIIB) Beats on Q2 Earnings & Sales, Ups 2022 Guidance [Jul-20-22 09:14AM] Biogen Inc. (BIIB) Q2 Earnings and Revenues Surpass Estimates [Jul-20-22 08:25AM] Earnings Beat, Increased FY22 Outlook, Rising Biosimilar Competition: Biogen's Q2 Highlights [Jul-20-22 08:05AM] Netflix, Tesla, Biogen, and More of Wednesdays Stock Market Movers [Jul-20-22 07:49AM] Biogen's stock is down 2.8% after missing on revenue in the second quarter [Jul-20-22 07:45AM] UPDATE 3-Biogen leans on new Alzheimer's drug to calm investor worries [Jul-20-22 07:12AM] Biogen leans on new Alzheimer's drug to calm investor worries [Jul-20-22 07:09AM] Netflix, Omnicom Rise Premarket; Baker Hughes, Merck Fall [Jul-20-22 04:01AM]
03-05-2022	PM	7:00 AM ET (May 3)	BIIB	Biogen	30,922	3.62	4.41	0.00	Biogen Non-GAAP EPS of $3.62 misses by $0.74, revenue of $2.53B beats by $30M [5/3/2022 7:04 AM]	205.44	-1.88 (-0.91%)	210.00	2.68 (1.29%)	192.67 - 468.55	1,303,641	1,110,000	6,830
Aduhelm woes, performance of multiple sclerosis drugs in focus for Biogen's Q1 earnings [5/2/2022 1:27 PM] Biogen, Scribe to develop additional gene therapy disease target [5/2/2022 11:23 AM] Biogen Non-GAAP EPS of $3.62 misses by $0.74, revenue of $2.53B beats by $30M [5/3/2022 7:04 AM] Biogen begins executive search to replace CEO [5/3/2022 7:32 AM] Biogen earnings falls short of consensus amid Aduhelm write-offs [5/3/2022 8:48 AM] Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More [May-02-22 03:55PM] Sage Therapeutics, Biogen Start Rolling Submission For Zuranolone In Major Depressive Disorder [May-02-22 12:58PM] Sage, Biogen start 'rolling submission' to FDA for depression drug [May-02-22 07:52AM] Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD) [May-02-22 06:30AM] The Zacks Analyst Blog Highlights Novo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and Biogen [May-02-22 06:22AM] Biogen to Eliminate Alzheimers Drug Infrastructure, Search for New CEO [May-03-22 07:23AM] Biogen Searches for New CEO in Wake of Struggles With Alzheimers Drug Launch [May-03-22 07:54AM] Biogen CEO Michel Vounatsos to step down [May-03-22 07:45AM] UPDATE 2-Biogen CEO to step down; drugmaker plans further Aduhelm cost cuts [May-03-22 07:10AM] Biogen CEO to step down; drugmaker plans further Aduhelm cost cuts [May-03-22 07:21AM] Biogen's Q1 profit and revenue lag estimates, weighed down by Alzheimer's drug [May-03-22 08:10AM] UPDATE 3-Biogen CEO to step down; drugmaker plans further Aduhelm cost cuts [May-03-22 07:10AM] Biogen Pops On New Plans For Its Embattled Alzheimer's Drug, Aduhelm [May-03-22 09:40AM] Biogen plans $1B in cost-savings as CEO steps down [May-03-22 09:45AM] Biogen chief to step down after Alzheimers drug flops [May-03-22 09:48AM] Biogen CEO to step down; drugmaker pulls back on Alzheimer's drug Aduhelm [May-03-22 07:21AM] UPDATE 4-Biogen CEO to step down; drugmaker pulls back on Alzheimer's drug Aduhelm [May-03-22 07:10AM] Biogen's 'Life After Aduhelm' Doesn't Include CEO Michel Vounatsos [May-03-22 11:18AM] Beset by challenges with its Alzheimers disease drug, Biogen pivots [May-03-22 12:47PM] Biogen (BIIB) Q1 Earnings Miss, Aduhelm Setback Leads to Rejig [May-03-22 10:55AM] UPDATE 5-Biogen CEO to step down; drugmaker pulls back on Alzheimer's drug Aduhelm [May-03-22 07:10AM] Biogen Inc. (BIIB) Q1 Earnings Miss Estimates [May-03-22 08:25AM] Drug companies are making an accounting change after the SEC cracked down on Biogen [May-03-22 03:04PM]
03-02-2022	PM	7:00 AM ET (Feb 3)	BIIB	Biogen Inc.	33,200	3.39	3.33	4.58	Biogen Non-GAAP EPS of $3.39 beats by $0.02, revenue of $2.74B beats by $120M [2/3/2022 7:00 AM]	220.59	-4.37 (-1.94%)	214.20	-10.76 (-4.78%)	212.56 - 468.55	1,632,047	1,590,000	37,055
Will Biogen Q4 earnings bring positive surprise amid Aduhelm woes? [2/2/2022 11:37 AM] Biogen Non-GAAP EPS of $3.39 beats by $0.02, revenue of $2.74B beats by $120M [2/3/2022 7:00 AM] Biogen falls after setting 2022 guidance below consensus [2/3/2022 7:56 AM] Were Hedge Funds Right About Biogen Inc. (BIIB)? [Feb-02-22 03:06PM] Integral Health Asset Management, LLC Buys McKesson Corp, Centene Corp, Abbott Laboratories, ... [Feb-02-22 01:38PM] Drug/Biotech Stocks Earnings on Feb 3: BIIB, LLY & MRK [Feb-02-22 12:31PM] AbbVie's (ABBV) Q4 Earnings Surpass Estimates, Sales Miss [Feb-02-22 11:40AM] Biotech Stock Roundup: GILD Q4 Earnings, REGN, MRNA's Regulatory Updates & More [Feb-02-22 11:27AM] Biogens Alzheimer drug Aduhelm proves drug prices are a lie [Feb-02-22 05:00AM] Biogen's stock falls 3.7% on earnings miss, says it brought in $1 million in sales of Alzheimer's drug in the fourth quarter [Feb-03-22 07:45AM] Biogen profit forecast misses estimates as Aduhelm weighs [Feb-03-22 07:42AM] UPDATE 2-Biogen profit forecast misses estimates as Aduhelm weighs [Feb-03-22 07:12AM] Biogen's stock falls 3.7% after announcing earnings, says it brought in $1 million in sales of Alzheimer's drug in the fourth quarter [Feb-03-22 07:55AM] Biogen Stock Drops as Results Fall Short. Sales of Alzheimers Drug Disappoint. [Feb-03-22 08:28AM] Biogen's Alzheimer's Struggles Continue; 'Minimal' Sales Expected This Year [Feb-03-22 08:53AM] Social media stocks fall on Meta rerating, Qualcomm shares down, pharmaceutical stocks decline [Feb-03-22 10:02AM] Biogen 2022 forecast below Street view on Alzheimer's drug uncertainty [Feb-03-22 07:42AM] UPDATE 3-Biogen 2022 forecast below Street view on Alzheimer's drug uncertainty [Feb-03-22 07:12AM] Meta Platforms, Spotify, Biogen Fall Premarket; T-Mobile Rises [Feb-03-22 03:18AM] Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates [Feb-03-22 08:25AM] Biogen outlines a gloomy forecast due to generics, Aduhelm controversy [Feb-03-22 12:59PM] Biogen (BIIB) Q4 Earnings Top, Stock Down on Weak 2022 View [Feb-03-22 12:06PM] Biogen's 2022 forecast well below Street view on Alzheimer's drug uncertainty [Feb-03-22 07:42AM] UPDATE 4-Biogen's 2022 forecast well below Street view on Alzheimer's drug uncertainty [Feb-03-22 07:12AM] 10 Biotech Stocks to Buy According to Matthew Strobecks Birchview Capital [Feb-03-22 02:36PM] Biogen Falls on Bleak Outlook for Aduhelm, Entry of Generics [Feb-03-22 07:40AM] Greatmark Investment Partners, Inc. Buys Amgen Inc, Invesco BulletShares 2023 Corporate Bond ... [Feb-03-22 05:38PM] Top 10 Stock Picks of Samuel Isalys OrbiMed Advisors [Feb-03-22 04:35PM]
20-10-2021	PM	7:00 AM ET (Oct 20)	BIIB	Biogen Inc.	40,200	4.77	4.15	8.84	Biogen EPS beats by $0.68, beats on revenue, boost FY outlook [10/20/2021 7:06 AM]	266.43	-1.69 (-0.63%)	271.00	2.87 (1.07%)	223.25 - 468.55	1,901,886	950,000	73,751
Will Biogen Q3 earnings see Alzheimer's drug Aduhelm impact? [10/19/2021 12:59 PM] Biogen, Sage expect marketing application for depression therapy in H2 2022 [10/19/2021 7:04 AM] Biogen EPS beats by $0.68, beats on revenue, boost FY outlook [10/20/2021 7:06 AM] Biogen raises guidance for 2021 despite slow uptake of new Alzheimer’s drug [10/20/2021 7:43 AM] Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022 [Oct-19-21 06:30AM] UPDATE 1-Biogen posts much smaller-than-expected sales of new Alzheimer's drug [Oct-20-21 07:16AM] Biogen posts much smaller-than-expected sales of new Alzheimer's drug [Oct-20-21 07:07AM] Biogen's stock is up on strong earnings; new Alzheimer's drug had $300,000 in sales in Q3 [Oct-20-21 07:49AM] Sage, Biogen now plan to submit depression drug candidate to FDA in second half of 2022 [Oct-20-21 07:53AM] Biogens Alzheimer Drug Sales Were Dismal. Earnings Are Lifting the Stock. [Oct-20-21 08:17AM] Biogen raises forecast despite disappointing Alzheimer's drug sales [Oct-20-21 07:07AM] Premarket Movers Wednesday - Novavax, Biogen, Netflix [Oct-20-21 04:45AM] Biogen Beats on Third Quarter Earnings and Raises Guidance [Oct-20-21 04:41AM] Biogen CEO Says Alzheimer's Uptake 'Is Delayed,' But Shares Pop On Earnings Beat [Oct-20-21 09:16AM] Biogen Inc. (BIIB) Q3 Earnings and Revenues Surpass Estimates [Oct-20-21 08:25AM] Novavax vaccine delays slump stock, Abbott Labs raises guidance, Biogen beats Q3 estimates [Oct-20-21 10:35AM] Biogen banks on government coverage to restart stalled Alzheimer's drug sales [Oct-20-21 07:07AM] Biogen Warns Alzheimer's Uptake Will Be Neither 'Explosive' Nor 'Linear' In 2022 [Oct-20-21 12:08PM] Sage, Biogen Plan to File Zuranolone NDA for MDD in 2022 [Oct-20-21 10:46AM] Biogen (BIIB) Q3 Earnings Top, Aduhelm Sales Negligible [Oct-20-21 10:21AM] Biogen inc (BIIB) Q3 2021 Earnings Call Transcript [Oct-20-21 01:00PM] Biotech Stock Roundup: BIIB's Q3 Earnings, REGN's COVID-19 Cocktail Update & More [Oct-20-21 11:38AM] 4 Healthcare Stocks Selling for Way Less Than Analysts Think Theyre Worth [Oct-20-21 01:23PM] Abbot Labs and Biogen Outshine Novavax in the Health Care Sector [Oct-20-21 10:34AM]
22-07-2021	PM	7:10 AM ET (Jul 22)	BIIB	Biogen Inc.	48,550	5.68	4.57	10.26	Biogen EPS beats by $1.08, beats on revenue [7/22/2021 7:03 AM]	326.65	3.69 (1.14%)	322.96	0.0 (0.00%)	223.25 - 468.55	1,389,788	1,660,000	12,133
Biogen Q2 2021 Earnings Preview [7/21/2021 1:50 PM] Anthem still weighing coverage decision on Biogen's Aduhelm [7/21/2021 12:25 PM] Biogen EPS beats by $1.08, beats on revenue [7/22/2021 7:03 AM] Biogen raises 2021 guidance; records $2 million quarterly sales from new Alzheimer’s drug [7/22/2021 7:46 AM] Biogen R&D chief pens letter to Alzheimer's community defending Aduhelm [7/22/2021 11:52 AM] Here's Why Cassava Sciences Is Surging Today [Jul-21-21 03:39PM] Alzheimer's Approval, COVID-19 Vaccines Put Spotlight On Biotech Sector, But What's Next? [Jul-21-21 11:49AM] Analysis: Biogen Alzheimer's drug slow to take off as U.S. Medicare wrestles with coverage [Jul-21-21 08:33AM] Mirimus, Inc. Forms Strategic Collaboration with Biogen to Develop RNAi-Based Therapeutics for Neurological Disease Indications [Jul-21-21 08:03AM] 2 Top Biotech Stocks to Buy Right Now [Jul-21-21 07:18AM] An open letter to the Alzheimers disease community from our Head of Research and Development, Alfred Sandrock, M.D., Ph.D. [Jul-22-21 07:05AM] UPDATE 1-Biogen raises 2021 revenue forecast, defends Alzheimer's drug approval [Jul-22-21 07:20AM] Biogen raises 2021 revenue forecast, defends Alzheimer's drug approval [Jul-22-21 07:07AM] Biogen Earnings, Sales Top Q2 Views; Stock Rises [Jul-22-21 07:33AM] Biogen defends Alzheimer's drug approval, reports $2 million in early sales [Jul-22-21 07:07AM] Biogen's beats on earnings, says it's also brought in $2 million in sales of Alzheimer's drug [Jul-22-21 07:54AM] UPDATE 2-Biogen defends Alzheimer's drug approval, reports $2 mln in early sales [Jul-22-21 07:20AM] Biogen pushes back against critics of Alzheimer's drug as early sales hit $2 million [Jul-22-21 07:11AM] Biogen pushes back against critics of Alzheimer's drug as early sales hit $2 million [Jul-22-21 07:07AM] Premarket Movers Thursday: CSX, Texas Instruments and AT&T [Jul-22-21 04:22AM] Biogen Sold $1.6M of Aduhelm in Weeks After Approval. Earnings Were Strong. [Jul-22-21 09:40AM] Live: Jim Cramer on AT&T, Airline Earnings, Biogen, Crypto, Uber [Jul-22-21 05:48AM] Biogen says uptake on new Alzheimers's drug slower than expected [Jul-22-21 07:11AM] Biogen blames misinformation for cloud over its Alzheimers drug [Jul-21-21 08:00PM] Heres How Much Biogen Sold of Aduhelm in the Weeks After Its Approval [Jul-22-21 10:30AM] AT&T, Crocs, Biogen top Q2 estimates, Didi shares dip as China regulatory woes persist [Jul-22-21 10:27AM] Biogen Inc. (BIIB) Tops Q2 Earnings and Revenue Estimates [Jul-22-21 08:25AM] Video: Jim Cramer on AT&T, Airline Earnings, Biogen, Crypto, Uber [Jul-22-21 05:48AM] Biogen's Q2 Profit Falls 70% As Tecfidera Competition Hits Topline [Jul-22-21 07:53AM] Biogen Revealed Early Sales of Its Controversial Alzheimers Drug In Its Earnings Release. What to Know. [Jul-22-21 11:03AM] Biogen Gains On Revising Guidance, Q2 Aduhelm Revenue At $2 Million [Jul-22-21 06:38AM] Biogen's Marquee Alzheimer's Drug Launches, But Sales Fall Slightly Short [Jul-22-21 11:18AM] Biogen (BIIB) Q2 Earnings Top, Aduhelm Early Sales Hit $2M [Jul-22-21 09:36AM] Biogen says uptake on new Alzheimer's drug slower than expected [Jul-22-21 07:11AM] Biogen says uptake on new Alzheimer's drug slower than expected [Jul-22-21 07:07AM] Biogen Revealed Early Sales of Its Controversial Alzheimers Drug. What to Know. [Jul-22-21 11:03AM] Biogen profit tumbles 71% on rising competition to multiple sclerosis drug [Jul-22-21 07:06AM] Biogen beats on earnings, says it's brought in $2 million in sales of Alzheimer's drug [Jul-22-21 02:11PM] Biogen, under pressure, tells investors it stands by the FDA review process for its Alzheimers drug [Jul-22-21 03:07PM]
22-04-2021	PM	7:00 AM ET (Apr 22)	BIIB	Biogen Inc.	40,990	5.34	5.07	9.14	Biogen EPS beats by $0.39, beats on revenue [4/22/2021 7:05 AM]	259.06	-10.79 (-4.00%)	259.99	-9.86 (-3.65%)	223.25 - 363.92	1,959,699	870,000	71,461
Biogen Q1 2021 Earnings Preview [4/21/2021 1:02 PM] Biogen EPS beats by $0.39, beats on revenue [4/22/2021 7:05 AM] Biogen boost EPS guidance for 2021; seeks aducanumab approval in additional markets [4/22/2021 8:07 AM] Biogen slides as analysts see no major surprises in Q1 results [4/22/2021 11:14 AM] Does Biogen Stand A Chance Of Topping Bearish First-Quarter Views? [Apr-21-21 04:36PM] Biogen, Inc. to Host Earnings Call [Apr-22-21 06:15AM] UPDATE 1-Biogen quarterly profit slumps about 71% on MS drug competition [Apr-22-21 07:16AM] Biogen quarterly profit slumps about 71% on MS drug competition [Apr-22-21 07:26AM] Biogen's stock is up, though revenue fell 25% for the quarter [Apr-22-21 07:47AM] Biogens Earnings Beat Forecasts. The Stock Is Rising. [Apr-22-21 08:14AM] Spinraza outweighs weak multiple sclerosis drug sales, drives Biogen profit beat [Apr-22-21 07:26AM] UPDATE 2-Spinraza outweighs weak multiple sclerosis drug sales, drives Biogen profit beat [Apr-22-21 07:16AM] Biogen Tops First-Quarter Expectations And Boosts Earnings Outlook [Apr-22-21 08:53AM] Biogen Inc. (BIIB) Surpasses Q1 Earnings and Revenue Estimates [Apr-22-21 08:25AM] UPDATE 3-Spinraza outweighs weak multiple sclerosis drug sales, drives Biogen profit beat [Apr-22-21 07:16AM] Biogen (BIIB) Q1 Earnings Top, Sales Down as Key Drugs Falter [Apr-22-21 09:18AM] Why Biogen's Better-Than-Expected Q1 Results Weren't Good Enough [Apr-22-21 10:16AM] Biogen Is Betting Big On Alzheimer's As Generics Slam Its Blockbusters [Apr-22-21 11:21AM] Biogen shares fall as Alzheimer's drug concerns cloud profit beat [Apr-22-21 07:26AM] UPDATE 4-Biogen shares fall as Alzheimer's drug concerns cloud profit beat [Apr-22-21 07:16AM] Biogen talks up approval plans for controversial Alzheimers drug as it nears FDA decision [Apr-22-21 12:36PM] Biogen's Shares Are Trading Lower On 71% Quarterly Profit Slump, Weak Tecfidera Sales [Apr-22-21 10:50AM] Biogen Inc (BIIB) Q1 2021 Earnings Call Transcript [Apr-22-21 02:30PM]
03-02-2021	PM	7:30 AM ET (Feb 3)	BIIB	Biogen Inc.	42,850	4.58	4.92	8.34	Biogen EPS misses by $0.18, beats on revenue [2/3/2021 7:15 AM]	263.55	-14.17 (-5.10%)	270.50	-7.22 (-2.60%)	223.25 - 374.99	2,228,039	1,390,046	69,122
Biogen EPS misses by $0.18, beats on revenue [2/3/2021 7:15 AM] Biogen Q4 2020 Earnings Preview [2/2/2021 1:00 PM] Biogen CEO sees 'financial reset in 2021' as Q4 results disappoint [2/3/2021 11:14 AM] Biogen Inc (BIIB) Q4 2020 Earnings Call Transcript [Feb-03-21 01:01PM] Biogen Off on Weaker-Than-Expected 2021 Forecast [Feb-03-21 08:39AM] Biogen Inc. (BIIB) Misses Q4 Earnings Estimates [Feb-03-21 08:35AM] Perrigo will not receive $400 million milestone payment [Feb-03-21 08:21AM] Biogen: Q4 Earnings Insights [Feb-03-21 07:19AM]
21-10-2020	PM	6:30 AM ET (Oct 21)	BIIB	Biogen Inc.	42,550	8.84	8.07	9.17	Biogen up 3% on earnings beat, guidance raised [10/21/2020 7:11 AM]	269.24	2.12 (0.80%)	264.01	-3.11 (-1.16%)	221.56 - 374.99	1,595,333	894,862	52,022

22-07-2020	PM	7:25 AM ET (Jul 22)	BIIB	Biogen Inc.	46,000	10.26	7.97	9.15	Biogen EPS beats by $2.25, beats on revenue [7/22/2020 7:07 AM]	282.96	2.77 (0.99%)	285.20	5.01 (1.79%)	215.78 - 374.99	656,540	1,205,017	73,379